Research in Social and Administrative Pharmacy
Volume 6, Issue 3 , Pages 221-231, September 2010

Consumers' views of pharmacogenetics—A qualitative study

  • Catherine A. Haddy, B.Pharm. (Hons.)

      Affiliations

    • School of Pharmacy and Medical Sciences, Sansom Institute, University of South Australia, Frome Road, Adelaide 5000, South Australia
  • ,
  • Helena M. Ward, B.Sc., Ph.D.

      Affiliations

    • School of Medicine, Flinders University, Adelaide, South Australia
  • ,
  • Manya T. Angley, B.Pharm., Ph.D.

      Affiliations

    • School of Pharmacy and Medical Sciences, Sansom Institute, University of South Australia, Frome Road, Adelaide 5000, South Australia
  • ,
  • Ross A. McKinnon, B.Pharm., Ph.D.

      Affiliations

    • School of Pharmacy and Medical Sciences, Sansom Institute, University of South Australia, Frome Road, Adelaide 5000, South Australia
    • Corresponding Author InformationCorresponding author. Tel.: +61-8-83022372; fax: +61-8-83011087.

published online 16 October 2009.

Abstract 

Background

Adverse drug reactions are recognized as a significant public health issue. Pharmacogenetics (PGx) provides a potential means of preventing some adverse drug reactions by predicting the optimal medication dose for an individual; however, PGx is rarely used in clinical practice. Thus far, there have been few studies investigating consumers' perceptions of the barriers to the implementation of PGx in clinical practice.

Objectives

This study explored the views of the general public regarding their current use of medications, and their experiences of side effects and opinions on PGx.

Methods

Members of the general public who suffered a chronic medical condition and/or had an immediate family member with a chronic medical condition were recruited to form 5 separate focus groups (n=35). Three separate age ranges were used in the focus groups. A questioning route was developed and used in focus groups to determine participants' experiences with medication use and opinions on PGx (referred to as “Personalized Medicine”). Focus group discussions were transcribed by 2 separate investigators, and qualitative analysis, based on the framework approach, was applied to the data. Data were independently coded to identify key themes then compared both within and between focus groups.

Results

A common theme was a desire to have a holistic approach to disease diagnosis and medication selection. A wide range of views were expressed by the focus group participants. Concerns were raised regarding the current level of side effects experienced with medications. Storage and privacy of genetic information, and the costs involved, were also seen as potential barriers to implementation of PGx.

Conclusions

PGx testing was seen as a potential positive contribution, but only if other factors were considered during the prescribing process. As participants desired a high level of information and effective communication from their health-care professionals, PGx education of clinicians and pharmacists will be essential to satisfy consumers' requirements.

Keywords: Pharmacogenetics, Personalized medicine, Consumer, Focus groups, Adverse drug reactions

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 25.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1551-7411(09)00104-1

doi:10.1016/j.sapharm.2009.08.002

Research in Social and Administrative Pharmacy
Volume 6, Issue 3 , Pages 221-231, September 2010